Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Thank you!
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Clinical Reference Laboratory Market Size
The global clinical reference laboratory market size was valued at around USD 45.6 billion in 2023 and is estimated to grow at 6.2% CAGR from 2024 to 2032. Clinical reference laboratories are presumed as a particular kind of laboratory which can perform high level advanced medical diagnostics including blood, urine, and surgical tissue tests.
To get key market trends
The above biological materials are acquired from practitioners, medical facilities, and other laboratories. Such tests are not limited to blood tests only, but also include advanced or genetic tests, as well as complex testing aimed at diagnosing specific conditions.
Clinical Reference Laboratory Market size in 2023:
USD 45.6 Billion
Forecast Period:
2024 – 2032
Forecast Period 2023 - 2032 CAGR:
6.2
2023 Value Projection:
USD 78 Billion
Historical Data for:
2021 – 2023
No of Pages:
135
Tables, Charts & Figures:
85
Segments Covered:
Service Type, Application, and Region
Growth Drivers:
Rising incidence of chronic and infectious diseases
Growing number of bio reference laboratories
Increasing number of diagnostic testing
Rising geriatric population
Pitfalls Challenges:
High cost of advanced technologies
Presence of stringent regulatory policies
What are the growth opportunities in this market?
Chronic and communicable diseases have become a leading factor propelling the clinical reference laboratory category’s growth. Furthermore, there exists a growing need in the market for diagnosis in order to treat and control chronic illnesses. The World Health Organization (WHO) presents a grave fact on the topic. Cardiovascular diseases contribute to an estimated 17.9 million deaths annually and are the commercial world’s top Non-Communicable Disease (NCD). Other significant factors are the cancers, which cause an estimated 9.3 million deaths; chronic respiratory diseases, an estimated 4.1 million deaths; complications associated with diabetes, kidney disease included, an estimated 2 million deaths.
The accumulating global burden of these diseases explains the need for a greater supply of other medical services especially diagnostics. These services are important in detecting disease early, managing them, and monitoring health status on an ongoing basis. As a result, there is a surge in the demand for various essential testing services from clinical reference laboratories. These include blood analysis, which encompasses genetic diagnostics, biomarker evaluation, and other related measures that are necessary in improving patient’s health and in the management of health in a long term.
The proliferation of bio reference laboratories, more tests being carried out, and the increase of older adult population are some of the reasons affecting the growth of the clinical reference laboratory industry. Due to the higher demographic age group being chronic patients and needing check-ups regularly, the need for global and specific medical diagnostic services are increasing. In addition to this, the growth of such kinds of laboratories that are equipping new tools seems to imply that there will be great growth in the market in the coming years.
Clinical Reference Laboratory Market Trends
The importance of diagnostic tests has grown remarkably and is now a primary tool through which diseases can be diagnosed early, use of personalized medicine and the control of chronic conditions has been done. This development is one of the factors that promote expansion in the market.
Due to the increasing global incidence of chronic diabetes, cardiovascular diseases, cancer, and respiratory disorders, there is an ever-growing need for routine testing. Patients suffering from these diseases tend to require regular monitoring and interventions leading to a constant need for laboratory facilities.
Therefore, in response to the increased growth, clinical reference laboratories are actively looking for areas of growth. New techniques such as genetic testing, molecular diagnostics, and biomarker assays have been developed. These innovations will provide more precise, faster, and thorough testing, allowing healthcare professionals to keep patients with chronic diseases in check.
For example, the U.S. National Institutes of Health (NIH), is increasing the potential of molecular diagnostics which by means of its all of U.S. Research Program. It includes collecting health information of various people and providing genetic tests to the participants, this program increases the amount of genomic testing available within clinical laboratories, and it paves the way towards precision medicine. By 2032 this segment is expected to reach USD 157.1 billion, this will allow the development of more tailored and successful treatment methods.
Moreover, with a rising popularity for preventive medicine, a greater number of people are started to demand for a diagnostic test in order to facilitate timely disease diagnosis. The previous trend is supported by the increasing number of health check-ups together with screening procedures for cancer and other infectious or metabolic diseases, which increase the number of tests in clinical reference laboratories.
These interactions all together provide a positive perspective for the prospects of the clinical reference laboratory industry.
Clinical Reference Laboratory Market Analysis
Learn more about the key segments shaping this market
Based on service type, the market is segmented into hospital-based, standalone, and clinic-based. The hospital-based segment dominated the market with the largest revenue of USD 22.3 billion in 2023 and is expected to grow at a significant CAGR over the forecast period.
Clinically, there are hospital-owned laboratories which are capable of performing basic and advanced diagnosis services, including conducting blood tests and molecular biology tests. Such diversity of diagnostic tools under one roof facilitates treatment delivery to the patients.
Also, standalone laboratories are no able to purchase advanced technologies and devices; however, hospital laboratories are able to which enables them to conduct advanced diagnostic tests which would be impossible for standalone laboratories to conduct. Such capability does not only increase the scenarios where all the diagnostic services would be useful but also the clinic’s ability to offer them strengthens the health team’s ability to make appropriate and timely decisions.
Also, the location of hospital-based laboratories in relation to where a patient would interface with a healthcare professional ensures that the patients have access to quick tests that are needed in critical medical situations such as emergencies. This quick turn around can be vital in life and death situations as instant steps have to be taken and therefore greatly augments the market development.
Learn more about the key segments shaping this market
Based on application, the clinical reference laboratory market is divided into clinical trials and laboratory medicine. The laboratory medicine segment of the market, which held a 67.6% share in 2023, is poised for substantial growth in the coming years.
Laboratory medicine is one of the core services in modern healthcare, since it generates diagnostic information that enables disease prevention, diagnosis and treatment. This segment includes clinical reference laboratories (CRLs) which perform high throughput biochemical testing to asses organ performance, identify metabolic abnormalities, and follow up chronical cases. For example, liver and kidney and function tests lipid panels are performed routinely to aid the clinicians in managing the patients appropriately.
Aside from the standard biochemical evaluation, it has been observed that CRLs are now utilizing advanced technologies such as polymerase chain reaction and next generation sequencing. These technologies support genetic testing and agent pathogen detection that are fast and accurate, which improves personalized medicine and targeted therapy.
Looking for region specific data?
In 2023, the U.S. led the North American market, generating a revenue of USD 16.9 billion.
In the U.S., a lot of people suffer from chronic diseases diabetes, cancer, autoimmune disorders among others. This therefore places great importance on the role of clinical reference laboratories CRL’s in diagnosis and monitoring. As reported by the Centers for Disease Control and Prevention (CDC), 38.4 million Americans had diabetes in 2021, this figure indicates a greater role of CRLs to avert the situation through targeted intervention. Biochemical investigations and molecular diagnostics are performed by CRLs to improve the quality of medical care and health of patients.
Certain agencies like the Clinical Laboratory Improvement Amendments (CLIA) and American food and drug administration FDA dominate the U.S. regulatory environment which ensures high levels of integrity are maintained with regard to operations of laboratory, accuracy of tests and safety of patients. This regulatory compliance strengthens the confidence in the clinical reference laboratories in the U.S.
Certain factors such as these influences enable the segment’s growth development to be grown at a higher level in the future years.
The UK is set to see a robust expansion in its clinical reference laboratory market from 2024 to 2032.
The existence of organizations such like the National Health Service (NHS) and numerous universities allows the UK to be at the forefront of medical researches. This stimulation aids the development of new medical diagnostic tests as well as hi-tech devices that augment the functions of clinical reference laboratories.
The laboratory medicine sector in the UK is further complemented by well trained manpower comprising pathologists, laboratory specialists and technicians. Their skills ensure the highest standard of diagnostic services and further development of laboratory services.
Japan's clinical reference laboratory market is poised for substantial growth between 2024 and 2032.
In light of Japan's demographic trends, it is arguably the most influenced case. This is due to the fact that Japan has one of the fastest growing ageing population that possesses a greater amount of chronic diseases thus the requirements of diagnostic services will exceed. This context is a great chance for clinical reference laboratories.
The ongoing trends of Japan towards more clinical target medicines, such as genomics, are in trend with the services provided by clinical reference laboratories. There is an increasing demand and revenue growth because of their ability to perform advanced genetic testing and specialized diagnostic services, especially in the field of cancer treatments and customers with rare genetic disorders.
Saudi Arabia's clinical reference laboratory market is on the brink of significant growth from 2024 to 2032.
As an implementation of Vision 2030, the government of Saudi Arabia is making large investments into healthcare. Such expenditures include healthcare constructions, advanced medical devices, and upgrading laboratory services that would increase the strength of clinical reference laboratories.
Clinical Reference Laboratory Market Share
The market is characterized by strong competition with international companies and small and medium companies competing to gain foothold in this market. One of the crucial strategies for the expansion of this market is the continuous deployment of new procedures and technologies for testing, which includes molecular, automation, and point of care. These innovations are a result of robust research and development investment made by the leading companies, which in turn shapes the future of the market.
Also, mergers, acquisitions, and strategic alliances are important tools for strengthening market position and increasing international coverage taking into account changes in the healthcare systems and regulatory frameworks. Additionally, the competitiveness of the market is also influenced by increased concern for the quality of service, accreditation for various services, and application of complex data analyses which improves the services provided and the clients’ confidence in the services offered to them.
Clinical Reference Laboratory Market Companies
Some of the eminent market participants operating in the clinical reference laboratory industry include:
Al Borg Medical Laboratories
Ampath Laboratories
ARUP Laboratories
Biolab
Eurofins Scientific
Laboratory Corporation of America Holdings
Laboratoires Réunis
Lifebrain Group
Lancet Laboratories
Mayo Clinic Laboratories
Medsol Diagnostics
Quest Diagnostics
Sonic Healthcare
Synlab Group
Unilabs
USP’s for Key Players:
Mayo Clinic Laboratories leverages extensive research-driven diagnostics with a vast test portfolio, ensuring high accuracy and specialized testing capabilities.
Quest Diagnostics provides nationwide accessibility with a broad network of laboratories, enabling fast turnaround times and comprehensive diagnostic solutions.
Sonic Healthcare specializes in high-quality pathology and laboratory medicine services, integrating advanced automation for efficient and precise clinical testing.
Clinical Reference Laboratory Industry News
In August 2023, the American Institute of Pathology & Laboratory Sciences (Ampath) opened its first reference laboratory in Gurgaon, expanding its presence in North India and marking its second reference lab in the country. This facility enhanced Ampath's capacity to provide high-quality diagnostic services, improving access to timely pathology and laboratory services for healthcare providers and patients in the region.
In July 2020, Synlab and Microba formed a partnership to launch the gut microbiome test MyBiome in Europe and Latin America. This innovative metagenomic sequence-based test offers comprehensive, actionable insights into individuals’ gut microbiomes. The collaboration enhanced SYNLAB’s diagnostic portfolio, positioning it as a leader in microbiome testing and meeting the growing demand for personalized healthcare solutions in clinical reference laboratories.
The clinical reference laboratory market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:
to Buy Section of this Report
Market, By Service Type
Hospital-based
Standalone
Clinic-based
Market, By Application
Clinical trials
Laboratory medicine
The above information is provided for the following regions and countries:
North America
U.S.
Canada
Europe
Germany
UK
France
Spain
Italy
Netherlands
Asia Pacific
China
Japan
India
Australia
South Korea
Latin America
Brazil
Mexico
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Author: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Who are the major players in the clinical reference laboratory market?+
Key players in the industry include Al Borg Medical Laboratories, Ampath Laboratories, ARUP Laboratories, Biolab, Eurofins Scientific, Laboratory Corporation of America Holdings, Laboratoires R
How big is the U.S. clinical reference laboratory industry?+
The U.S. market was valued at USD 16.9 billion in 2023, led by the high prevalence of chronic diseases such as diabetes, cancer, and autoimmune disorders.
How big is the clinical reference laboratory market?+
The market size of clinical reference laboratory reached USD 45.6 billion in 2023 and is estimated to grow at a 6.2% CAGR from 2024 to 2032, driven by the rising incidence of chronic and infectious diseases.
What was the market share of the laboratory medicine segment in 2023?+
The laboratory medicine segment held over 67.6% market share in 2023, highlighting its critical role in modern healthcare for disease prevention, diagnosis, and treatment.